On Tuesday, Esperion Therapeutics Inc (NASDAQ: ESPR) was -6.84% drop from the session before settling in for the closing price of $1.17. A 52-week range for ESPR has been $0.69 – $3.94.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 17.50% over the past five years. When this article was written, the company’s average yearly earnings per share was at 45.54%. With a float of $194.58 million, this company’s outstanding shares have now reached $196.66 million.
Let’s look at the performance matrix of the company that is accounted for 304 employees. In terms of profitability, gross margin is 65.3%, operating margin of -15.4%, and the pretax margin is -59.03%.
Esperion Therapeutics Inc (ESPR) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Esperion Therapeutics Inc stocks. The insider ownership of Esperion Therapeutics Inc is 1.83%, while institutional ownership is 57.31%. The most recent insider transaction that took place on Jun 17 ’25, was worth 33,793. Before that another transaction happened on Jun 17 ’25, when Company’s Officer proposed sale 7,229 for $1.15, making the entire transaction worth $8,329.
Esperion Therapeutics Inc (ESPR) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 45.54% per share during the next fiscal year.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
You can see what Esperion Therapeutics Inc (ESPR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.79, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.17 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Esperion Therapeutics Inc (NASDAQ: ESPR) saw its 5-day average volume 2.74 million, a negative change from its year-to-date volume of 4.84 million. As of the previous 9 days, the stock’s Stochastic %D was 45.35%. Additionally, its Average True Range was 0.08.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 25.85%, which indicates a significant decrease from 61.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 78.90% in the past 14 days, which was lower than the 78.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9694, while its 200-day Moving Average is $1.7583. Nevertheless, the first resistance level for the watch stands at $1.1467 in the near term. At $1.2033, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.2367. If the price goes on to break the first support level at $1.0567, it is likely to go to the next support level at $1.0233. Assuming the price breaks the second support level, the third support level stands at $0.9667.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
There are 198,199K outstanding shares of the company, which has a market capitalization of 216.03 million. As of now, sales total 332,310 K while income totals -51,750 K. Its latest quarter income was 65,000 K while its last quarter net income were -40,460 K.
